Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1990-10-31
1992-04-07
Friedman, S. J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31505
Patent
active
051028794
ABSTRACT:
The present invention is novel derivatives of pyrrolo[3,2-d]pyrimidines and pharmaceutical compositions and methods of use therefor. The derivatives are inhibitors of purine nucleoside phosphorylase selectively cytotoxic to T-cells but not to B-cells in the presence of 2'-deoxyguanosine and, therefore, are for use in the treatment of autoimmune diseases, gout, psoriasis or rejection of transplantation.
REFERENCES:
patent: 4923872 (1990-05-01), Kostlan et al.
patent: 4988702 (1991-01-01), Kostlan et al.
J. Org. Chem., 1979, 44:3826.
Cancer Res., 1986, 46:1774 Stoeckler, et al.
Kostlan Catherine R.
Sircar Jagadish C.
Friedman S. J.
Thierstein Joan
Warner-Lambert & Company
LandOfFree
Method of treating gout with novel 9-deazaguanines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating gout with novel 9-deazaguanines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating gout with novel 9-deazaguanines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1895443